- Home
- SPRO vs AKA Comparison
SPRO vs AKA Comparison
Compare SPRO & AKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- AKA
- Stock Information
- Founded
- SPRO 2013
- AKA 2018
- Country
- SPRO United States
- AKA United States
- Employees
- SPRO N/A
- AKA N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- AKA Catalog/Specialty Distribution
- Sector
- SPRO Health Care
- AKA Consumer Discretionary
- Exchange
- SPRO Nasdaq
- AKA Nasdaq
- Market Cap
- SPRO 107.5M
- AKA 110.4M
- IPO Year
- SPRO 2017
- AKA 2021
- Fundamental
- Price
- SPRO $1.87
- AKA $10.87
- Analyst Decision
- SPRO Buy
- AKA Strong Buy
- Analyst Count
- SPRO 4
- AKA 3
- Target Price
- SPRO $5.00
- AKA $24.33
- AVG Volume (30 Days)
- SPRO 798.2K
- AKA 3.9K
- Earning Date
- SPRO 08-12-2025
- AKA 08-06-2025
- Dividend Yield
- SPRO N/A
- AKA N/A
- EPS Growth
- SPRO N/A
- AKA N/A
- EPS
- SPRO N/A
- AKA N/A
- Revenue
- SPRO $48,576,000.00
- AKA $598,107,000.00
- Revenue This Year
- SPRO N/A
- AKA $7.23
- Revenue Next Year
- SPRO N/A
- AKA $4.04
- P/E Ratio
- SPRO N/A
- AKA N/A
- Revenue Growth
- SPRO N/A
- AKA 7.67
- 52 Week Low
- SPRO $0.51
- AKA $7.00
- 52 Week High
- SPRO $3.22
- AKA $32.25
- Technical
- Relative Strength Index (RSI)
- SPRO 35.23
- AKA 46.40
- Support Level
- SPRO $1.80
- AKA $10.43
- Resistance Level
- SPRO $2.38
- AKA $11.15
- Average True Range (ATR)
- SPRO 0.12
- AKA 0.46
- MACD
- SPRO -0.02
- AKA -0.05
- Stochastic Oscillator
- SPRO 12.07
- AKA 29.23
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.